John S. McBride

CIK 1618251 · Chief Operating Officer · last filed 2026-01-16

John S. McBride is a Chief Operating Officer who has filed 13 SEC Form 4 insider transactions across 3 companies since 2014. The most recent filing, for ELDN, was dated Jan 16, 2026. Across all open-market trades the lifetime net is −$315.2K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $11.7K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

$11.7K

Companies

3

Total Filings

13

Lifetime Open-Market Net

-$315.2K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
ELDN	Director	3,430	$3.40	$11.7K	$0	5	2026-01-16
Eledon Pharmaceuticals, Inc. (NVUS) Delisted	Director	—	—	—	$0	4	2020-09-15
Eledon Pharmaceuticals, Inc. (TKAI) Delisted	Chief Operating Officer	0	—	—	-$315.2K	4	2015-12-17

Recent Filings

13 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2026-01-16	ELDN	Exer (M)	+3,430	$0	EDGAR
2025-01-13	ELDN	Grant (A)	—	$0	EDGAR
2023-05-02	ELDN	Grant (A)	—	$0	EDGAR
2023-02-02	ELDN	Grant (A)	—	$0	EDGAR
2022-02-02	ELDN	Grant (A)	—	$0	EDGAR
2020-09-15	Eledon Pharmaceuticals, Inc. (NVUS) Delisted	Grant (A)	—	$0	EDGAR
2019-07-15	Eledon Pharmaceuticals, Inc. (NVUS) Delisted	Grant (A)	—	$0	EDGAR
2018-06-14	Eledon Pharmaceuticals, Inc. (NVUS) Delisted	Grant (A)	—	$0	EDGAR
2017-07-05	Eledon Pharmaceuticals, Inc. (NVUS) Delisted	Grant (A)	—	$0	EDGAR
2015-12-17	Eledon Pharmaceuticals, Inc. (TKAI) Delisted	Grant (A)	—	$0	EDGAR

Showing 1–10 of 13

Page 1 of 2 Next

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.